News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,290 Results
Type
Article (8039)
Company Profile (140)
Press Release (476206)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166756)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9761)
Job Trends (8574)
News (238215)
Policy (17900)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33162)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10368)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3624)
Cardiovascular disease (217)
Career advice (247)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47841)
Collaboration (1236)
Commercialization (3)
Compensation (1444)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5606)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4175)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73562)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87586)
Executive appointments (698)
FDA (12362)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (906)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9325)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (42)
IPO (12388)
IRA (2)
Job creations (1970)
Job search strategy (236)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5211)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (502)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (525)
Marketing (8)
MASH (118)
Medical device (8652)
Medtech (8792)
Mergers & acquisitions (14380)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1815)
NextGen: Class of 2026 (3154)
Non-profit (847)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (471)
Patient recruitment (501)
Peanut (31)
People (41234)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15457)
Phase 2 (21367)
Phase 3 (14387)
Pipeline (7135)
Policy (18)
Postmarket research (1572)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14789)
Reports (19)
Research institute (581)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (120)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (91)
Last 7 days (541)
Last 30 days (1611)
Last 365 days (19148)
2026 (11894)
2025 (19251)
2024 (22986)
2023 (26541)
2022 (34590)
2021 (37180)
2020 (33470)
2019 (23281)
2018 (17470)
2017 (18767)
2016 (17918)
2015 (24268)
2014 (21683)
2013 (18136)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17873)
Australia (2097)
California (11842)
Canada (3114)
China (513)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24611)
Florida (1770)
Georgia (371)
Hawaii (3)
Idaho (46)
Illinois (693)
India (48)
Indiana (314)
Iowa (14)
Japan (396)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1187)
Massachusetts (7802)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2599)
New Mexico (12)
New York (2799)
North Carolina (1262)
North Dakota (4)
Northern California (5926)
Ohio (275)
Oklahoma (14)
Oregon (16)
Pennsylvania (2239)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4914)
Tennessee (119)
Texas (1913)
United States (38509)
Utah (357)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (917)
West Virginia (1)
Wisconsin (73)
484,290 Results for "nuvasive inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Globus Medical Completes Merger with NuVasive
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasive, Inc.
September 1, 2023
·
7 min read
Business
NuVasive Announces Second Quarter 2023 Financial Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023.
August 2, 2023
·
25 min read
Biotech Beach
NuVasive to Participate in Upcoming March 2023 Investor Conferences
NuVasive, Inc. announced that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies’ recent merger announcement and other business topics.
February 27, 2023
·
6 min read
Business
NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
NuVasive, Inc. announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023 , after the close of the market.
July 24, 2023
·
2 min read
Business
NuVasive Announces First Quarter 2023 Financial Results
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023.
May 10, 2023
·
22 min read
Biotech Beach
NuVasive Celebrates 20-Year Milestone of the XLIF Procedure
NuVasive, Inc. announced today the 20-year milestone achievement of its lateral lumbar procedure, extreme lateral interbody fusion (XLIF).
March 13, 2023
·
5 min read
Deals
NuVasive Shareholders Approve Merger Agreement with Globus Medical
NuVasive, Inc. (NASDAQ: NUVA) today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company’s merger agreement with Globus Medical (NYSE: GMED).
April 27, 2023
·
9 min read
Biotech Beach
NuVasive to Participate in Upcoming Global Spine Conferences
NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced its continued participation at various global conferences throughout April and May.
April 11, 2023
·
3 min read
Business
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results
NuVasive, Inc. announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market.
May 4, 2023
·
2 min read
Biotech Beach
NuVasive to Participate in Upcoming Spine Society Annual Conferences
NuVasive, Inc. today announced its continued participation at the 2023 Spine Summit held March 16-19 in Miami and the International Meeting on Advanced Spine Techniques.
March 14, 2023
·
3 min read
1 of 48,429
Next
